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Introduction

The National Cholesterol Education Program periodically
produces Adult Treatment Panel (ATP) updates as warranted by
current clinical scientific research in cholesterol management.1
Each of the guideline reports, ATP I, II, and III, has a major role
in guiding physicians how to treat abnormal cholesterol levels.
Recent clinical trials demonstrate that LDL-lowering therapy
with statins (HMG-CoA inhibitors) reduces total mortality,
coronary mortality, major coronary events, coronary procedures
and strokes in patients with established coronary heart disease.1
However, the ATP III has cited active or chronic liver disease as an
absolute contraindication to the use of statins. The reason for this
contraindication goes back to the initial clinical trials of Lipitor
(atorvastatin), which demonstrated that persistent elevations (> 3
times the upper limit of normal) in serum transaminases occurred
in 0.7% of patients who received atorvastatin. The incidence of
these abnormalities was 0.2%, 0.2%, 0.6% and 2.3% for 10, 20, 40
and 80 mg atorvastatin, respectively.2 Based on this information,
the recommendation held that liver function tests should be
performed before the initiation of treatment with statins, following
each dosage increase, and periodically thereafter.
Although several reports of significant liver injury associated
with statins have appeared in the literature, in reality it occurs
rarely. Current labeling of statins is ambiguous; for example,
what exactly does active liver disease or persistent unexplained
liver function tests (LFTs) elevations mean? Also there is an
assumption that acute hepatotoxicity that develops in a patient
with impaired liver function would potentially be more fatal,
although evidence-based data to support this theory are lacking.
The fact remains that statins are the most efficacious drugs for
decreasing low-density lipoprotein cholesterol levels, and cardiovascular disease is the leading cause of mortality in the United
States. Thus, it is important to establish whether statin therapy
should be withheld from patients with liver disease.

Risk of Statin Hepatotoxicity

The following question must be addressed: are patients with
elevated liver enzymes at a higher risk for statin hepatotoxicity?
Chalasani et al and Vuppalanchi et al evaluated the affect
of starting statin therapy on the LFTs among patients with
baseline normal LFTs and those with baseline abnormal LFTs.
They determined that patients with baseline LFT elevation
had a greater incidence of a mild to moderate increase in LFTs
during treatment as compared to those without baseline LFT
abnormalities. The study also compared patients on statin
therapy with baseline elevated LFTs to patients with elevated
baseline LFTs and no history of statin use. The study showed
elevations in LFTs regardless of statin use. Therefore, the study
surmised that elevations in LFTs in patients with baseline
abnormalities while using statins may be due to underlying liver
disease and not statin use.3,4
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One of the most common causes of undiagnosed abnormal LFTs
is nonalcoholic steatohepatitis (NASH). NASH is characterized
by steatosis, inflammation and occasionally fibrosis of the liver
that can progress to cirrhosis. Rallidis et al studied the safety
and efficacy of pravastatin treatment on histological markers
of disease activity in patients with NASH. The study suggested
a possible beneficial role of statins in the treatment of NASH
and showed that the patients with NASH were not at an
increased risk of LFT abnormities secondary to statin use.5 This
clarification is important because many patients with NASH are
at a higher risk for cardiac events due to common co-morbidities
such as metabolic syndrome, hypercholesterolemia, obesity and
diabetes.
In clinical practice, the treatment of hyperlipidemia may
necessitate an increase in statin dosage to achieve the target goals
recommended by the ATP III. This leads to increased concerns
about statin-induced hepatotoxicity in patients with chronic
liver disease who require high doses of statin. This concern stems
from older clinical trials which showed an increased risk of LFT
elevations in patients taking high dose statins.2 A recent study by
Lewis et al compared pravastatin 80 mg to a placebo in a doubleblind clinical trial. The medications were administered daily to
hypercholesterolemic subjects greater than 18 years of age with
at least a six-month history of compensated chronic liver disease
and a low-density lipoprotein cholesterol (LDL-C) level greater
than or equal to 100 mg/dL. In comparison to placebo, highdose pravastatin (80 mg/day) significantly lowered LDL, total
cholesterol, and triglycerides and was safe and well tolerated.6
Recent research also contests the need for for routine transaminase
screening in patients taking statins. In a study by Smith et al, 1002
patients on statins were tested, and 10 (1%) of the patients were
identified as having significant LFT elevations while 5 (0.5%)
patients were identified as having moderate LFT elevations.
None of the elevations appeared to be directly related to statin
use, and no adverse outcomes were related to these abnormal lab
values.7 Therefore, the risk of severe transaminase elevations with
statin use is low. In addition, routine transaminase monitoring
may be unnecessary since it has low yield and excessive cost. The
monitoring may also lead to unnecessary evaluation of slightly
abnormal laboratory findings as well as the discontinuation of a
highly effective medication.

The Liver Expert Panel and Final Conclusions

The National Lipid Association (NLA) is a nonprofit, multidisciplinary medical society focused on enhancing the practice of
lipid management in clinical medicine. The Task Force, created
in June of 2005, was a two-year independent NLA initiative
to extensively review and evaluate the safety of statins and
other lipid-modifying drugs.8 After compilation of the analysis
and commissioned research, these experts presented their
conclusions to four Expert Panels who reviewed and considered
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the evidence relative to their respective fields of expertise:
nephrology, hepatology and neurology.
The Liver Expert Panel published their findings in the American
Journal of Cardiology in 2006. The panel’s key message was that
there is no proof that statins cause life-threatening liver damage.
LFT elevations are usually reversible after stopping the statin
therapy and do not cause long-term damage. Routine liver
enzyme monitoring is not needed during statin therapy. If an
isolated asymptomatic transaminase level of one to three times
the upper limits of normal is detected, the statin does not need
to be discontinued. If the transaminase level is more than three
times the upper limits of normal during routine evaluation, the
test should be repeated; if it is still elevated, further evaluation
should be pursued. Although routine transaminase monitoring
in patients taking statins is unnecessary, clinicians should be
alert to patient reports of jaundice, malaise, fatigue and other
possible signs of hepatotoxicity. If there is an objective evidence
of significant liver injury, the statin should be discontinued. In
conclusion, statin therapy can be safely administered to patients
with chronic liver disease, compensated cirrhosis, and NASH.8
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